{"id":"avtx-801","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":{"chemblId":"CHEMBL5847740","moleculeType":null,"molecularWeight":"362.44"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AVTX-801 uses a viral vector to deliver a healthy copy of the gene to the patient's cells, potentially correcting the underlying genetic defect. This approach has shown promise in treating a range of genetic diseases, including those caused by mutations in the gene responsible for the disorder being targeted by AVTX-801.","oneSentence":"AVTX-801 is a gene therapy that aims to treat certain genetic disorders by replacing or repairing faulty genes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:30:08.579Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of Methylmalonic acidemia"}]},"trialDetails":[{"nctId":"NCT05402332","phase":"PHASE2","title":"Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG (AVTX-801)","status":"NOT_YET_RECRUITING","sponsor":"Eva Morava-Kozicz","startDate":"2026-10-01","conditions":"PGM1-CDG - Phosphoglucomutase 1-Related Congenital Disorder of Glycosylation","enrollment":8},{"nctId":"NCT05402384","phase":"PHASE2","title":"AVTX-801 D-galactose Supplementation in SLC35A2-CDG","status":"NOT_YET_RECRUITING","sponsor":"Eva Morava-Kozicz","startDate":"2027-01","conditions":"SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["D-Galactose"],"phase":"phase_2","status":"active","brandName":"AVTX-801","genericName":"AVTX-801","companyName":"Eva Morava-Kozicz","companyId":"eva-morava-kozicz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AVTX-801 is a gene therapy that aims to treat certain genetic disorders by replacing or repairing faulty genes. Used for Treatment of Methylmalonic acidemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}